文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

感染与氟喹诺酮类药物使用与主动脉瘤或主动脉夹层风险的关联

Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.
PubMed 文献 · JAMA Intern Med · 2020-01-01
一句话结论在因适应证感染使用氟喹诺酮类药物的患者中,与阿莫西林-克拉维酸、氨苄西林-舒巴坦或广谱头孢菌素相比,氟喹诺酮类药物未增加主动脉瘤或主动脉夹层风险。

这项巢式病例对照研究基于2009年1月1日至2015年11月30日全国人群健康保险理赔数据库,纳入21 651 176名成人,分析28 948例主动脉瘤或主动脉夹层(AA/AD)病例与289 480名匹配对照。在结局发生前60天风险窗内,任何适应证感染的AA/AD校正OR为1.73(95%CI 1.66-1.81),其中败血症(OR 3.16,95%CI 2.63-3.78)和腹腔感染(OR 2.99,95%CI 2.45-3.65)风险最高。在相同适应证感染患者中,氟喹诺酮类药物与阿莫西林-克拉维酸或氨苄西林-舒巴坦联合用药相比(OR 1.01,95%CI 0.82-1.24)、与广谱头孢菌素相比(OR 0.88,95%CI 0.70-1.11),AA/AD风险均未增加。作者认为,对适应证感染患者,对AA/AD风险的担忧不应阻挠氟喹诺酮类药物的使用。

要点

  • 在适应证感染患者中,氟喹诺酮类药物与阿莫西林-克拉维酸或氨苄西林-舒巴坦相比,AA/AD校正OR为1.01(95%CI 0.82-1.24),未达统计学显著。
  • 在适应证感染患者中,氟喹诺酮类药物与广谱头孢菌素相比,AA/AD校正OR为0.88(95%CI 0.70-1.11),未达统计学显著。
  • 任何适应证感染与无感染相比,AA/AD校正OR为1.73(95%CI 1.66-1.81)。
  • 败血症(OR 3.16,95%CI 2.63-3.78)和腹腔感染(OR 2.99,95%CI 2.45-3.65)的AA/AD风险最高。
  • 作者认为,对适应证感染患者,对AA/AD风险的担忧不应阻挠氟喹诺酮类药物的使用。

适用人群与场景

  • 2009年1月1日至2015年11月30日全国人群健康保险理赔数据库中的成人患者,共21 651 176名。
  • 分析纳入28 948例AA/AD病例和289 480名匹配对照(71.37%男性;平均[SD]年龄67.41[15.03]岁)。
  • 暴露为结局发生前60天风险窗内的感染和抗生素使用。

研究设计与关键结果

  • 研究类型:巢式病例对照研究;数据库覆盖2009年1月1日至2015年11月30日;分析时间为2019年4月至2020年3月。
  • 样本量:21 651 176名成人中,纳入28 948例AA/AD病例与289 480名匹配对照,按年龄、性别和随访时间以风险集采样1:10匹配。
  • 主要终点:任何适应证感染的AA/AD校正OR为1.73(95%CI 1.66-1.81)。
  • 感染类型:败血症OR 3.16(95%CI 2.63-3.78),腹腔感染OR 2.99(95%CI 2.45-3.65),风险最高。
  • 氟喹诺酮类 vs 阿莫西林-克拉维酸或氨苄西林-舒巴坦:在适应证感染患者中,AA/AD校正OR为1.01(95%CI 0.82-1.24)。
  • 氟喹诺酮类 vs 广谱头孢菌素:在适应证感染患者中,AA/AD校正OR为0.88(95%CI 0.70-1.11)。
  • 亚组和敏感性分析中,氟喹诺酮类无关联的结果保持稳健。

证据类型、等级与局限

  • 证据类型:巢式病例对照研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对适应证感染患者,对AA/AD风险的担忧不应阻挠氟喹诺酮类药物的使用。
  • 结果强调在使用真实世界数据评估抗生素安全性时,需考虑合并感染的影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Prior observational studies have suggested that fluoroquinolone use may be associated with more than 2-fold increased risk of aortic aneurysm or aortic dissection (AA/AD). These studies, however, did not fully consider the role of coexisting infections and the risk of fluoroquinolones relative to other antibiotics.

OBJECTIVE: To estimate the risk of AA/AD associated with infections and to assess the comparative risk of AA/AD associated with fluoroquinolones vs other antibiotics with similar indication profiles among patients with the same types of infections.

DESIGNS, SETTINGS, AND PARTICIPANTS: This nested case-control study identified 21 651 176 adult patients from a nationwide population-based health insurance claims database from January 1, 2009, to November 30, 2015. Each incident case of AA/AD was matched with 10 control individuals by age, sex, and follow-up duration in the database using risk-set sampling. Analysis of the data was conducted from April 2019 to March 2020.

EXPOSURES: Infections and antibiotic use within a 60-day risk window before the occurrence of AA/AD.

MAIN OUTCOMES AND MEASURES: Conditional logistic regression was used to estimate the odds ratios (ORs) and 95% CIs comparing infections for which fluoroquinolones are commonly used with no infection within a 60-day risk window before outcome occurrence, adjusting for baseline confounders and concomitant antibiotic use. The adjusted ORs comparing fluoroquinolones with antibiotics with similar indication profiles within patients with indicated infections were also estimated.

RESULTS: A total of 28 948 cases and 289 480 matched controls were included (71.37% male; mean [SD] age, 67.41 [15.03] years). Among these, the adjusted OR of AA/AD for any indicated infections was 1.73 (95% CI, 1.66-1.81). Septicemia (OR, 3.16; 95% CI, 2.63-3.78) and intra-abdominal infection (OR, 2.99; 95% CI, 2.45-3.65) had the highest increased risk. Fluoroquinolones were not associated with an increased AA/AD risk when compared with combined amoxicillin-clavulanate or combined ampicillin-sulbactam (OR, 1.01; 95% CI, 0.82-1.24) or with extended-spectrum cephalosporins (OR, 0.88; 95% CI, 0.70-1.11) among patients with indicated infections. The null findings for fluoroquinolone use remained robust in different subgroup and sensitivity analyses.

CONCLUSIONS AND RELEVANCE: These results highlight the importance of accounting for coexisting infections while examining the safety of antibiotics using real-world data; the findings suggest that concerns about AA/AD risk should not deter fluoroquinolone use for patients with indicated infections.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Dong YH, Chang CH, Wang JL, et al. Association of Infections and Use of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection. JAMA Intern Med. 2020. PMID: 32897358. doi:10.1001/jamainternmed.2020.4192

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。